Dashboard
Manage Tickers

CUECue Biopharma, Inc.

Nasdaq cuebiopharma.com


$ 1.66 $ -0.09 (-5.17 %)    

Monday, 13-May-2024 15:43:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 442.96 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.64 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 217.46 $ -2.45 (-1.12 %)
$ 1.65
$ 1.82
$ 0.00 x 0
$ 0.00 x 0
$ 1.66 - $ 1.82
$ 1.30 - $ 4.89
98,120
na
81.62M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-21-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-16-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-14-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cue-biopharma-q1-2024-adj-eps-025-beats-028-estimate
Cue Biopharma Q1 2024 Adj EPS $(0.25) Beat...
05/09/2024 20:57:19

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) ...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
05/02/2024 20:31:10

forecasting-the-future-4-analyst-projections-for-cue-biopharma
Forecasting The Future: 4 Analyst Projecti...
04/09/2024 14:01:21

stifel-maintains-buy-on-cue-biopharma-maintains-8-price-target
Stifel Maintains Buy on Cue Biopharma, Mai...
04/09/2024 12:46:28

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and maintains $8 price target.

oppenheimer-maintains-outperform-on-cue-biopharma-maintains-10-price-target
Oppenheimer Maintains Outperform on Cue Bi...
04/09/2024 12:22:07

Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.

cue-biopharma-q1-eps-028-misses-027-estimate-sales-182m-beat-113m-estimate
Cue Biopharma Q1 EPS $(0.28) Misses $(0.27...
04/08/2024 20:06:32

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27...

piper-sandler-reiterates-overweight-on-cue-biopharma-maintains-8-price-target
Piper Sandler Reiterates Overweight on Cue...
04/03/2024 16:01:11

Piper Sandler analyst Edward Tenthoff reiterates Cue Biopharma (NASDAQ:CUE) with a Overweight and maintains $8 price target.

why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Clover Health Investments Shares Are T...
03/13/2024 17:18:56

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

jefferies-initiates-coverage-on-cue-biopharma-with-buy-rating-announces-price-target-of-6
Jefferies Initiates Coverage On Cue Biopha...
03/13/2024 13:02:38

Jefferies analyst Maury Raycroft initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Targ...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
01/01/2024 21:30:54

cue-biopharma-q3-eps-024-beats-034-estimate-sales-210m-beat-113m-estimate
Cue Biopharma Q3 EPS $(0.24) Beats $(0.34)...
11/09/2023 22:38:06

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.34) ...

piper-sandler-maintains-overweight-on-cue-biopharma-raises-price-target-to-8
Piper Sandler Maintains Overweight on Cue ...
11/06/2023 15:40:59

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and raises the price target fro...

cue-biopharma-presents-new-data-from-phase-1-trials-of-cue-101-in-head-and-neck-cancer-and-cue-102-in-wilms-tumor-1-positive-cancers-at-sitc-2023
Cue Biopharma Presents New Data From Phase...
11/03/2023 16:04:09

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients...

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
10/03/2023 18:37:58

  On Tuesday, 647 companies set new 52-week lows.

stocks-that-hit-52-week-lows-on-monday
Stocks That Hit 52-Week Lows On Monday
10/02/2023 17:00:10

  On Monday, 369 companies set new 52-week lows.

cue-biopharma-has-completed-patient-enrollment-in-its-phase-1-trial-of-cue-101-in-combination-with-keytruda-pembrolizumab-as-first-line-treatment-for-human-papilloma-virus-positive-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma
Cue Biopharma Has Completed Patient Enroll...
09/26/2023 12:06:02

cue-biopharma-and-2-other-stocks-under-3-insiders-are-buying
Cue Biopharma And 2 Other Stocks Under $3 ...
08/30/2023 11:49:47

The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confid...

cue-biopharma-q2-eps-029-beats-030-estimate-sales-138m-beat-121m-estimate
Cue Biopharma Q2 EPS $(0.29) Beats $(0.30)...
08/09/2023 20:47:42

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.30) ...

earnings-scheduled-for-august-9-2023
Earnings Scheduled For August 9, 2023
08/09/2023 08:54:09

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on r...

oppenheimer-assumes-cue-biopharma-at-outperform-announces-price-target-of-10
Oppenheimer Assumes Cue Biopharma at Outpe...
06/26/2023 10:50:38

Oppenheimer analyst Mark Breidenbach assumes Cue Biopharma (NASDAQ:CUE) with a Outperform rating and announces Price Target ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION